Silencing of indoleamine 2,3-dioxygenaseenhances dendritic cell immunogenicity and antitumour immunity in cancer patients

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 280-288

  Sioud, Mouldy ^a   Sæbøe Larssen, Stein ^a   Hetland, Thea Eline ^a   Kærn, Janne ^a   Mobergslien, Anne ^a   Kvalheim, Gunnar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer vaccine; Dendritic cells; Indoleamine 2,3 dioxygenase; siRNA

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; SMALL INTERFERING RNA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CASE REPORT; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE SILENCING; HUMAN; IMMUNOGENICITY; OVARY CANCER; PRIORITY JOURNAL; SAFETY; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR IMMUNITY;

CANCER VACCINES; DENDRITIC CELLS; FEMALE; GENE SILENCING; GENITAL NEOPLASMS, FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TELOMERASE;

EID: 84879682811     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1922     Document Type: Article

References (41)

1. Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature 449: 419-426, 2007. (Pubitemid 47509552)
2. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998. (Pubitemid 28155090)
3. Jego G, Pascual V, Palucka AK and Banchereau J: Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 8: 124-139, 2005.
4. Shaw J, Wang YH, Ito T, Arima K and Liu YJ: Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 115: 3051-3057, 2010.
5. Steinman RM, Hawiger D and Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711, 2003. (Pubitemid 37174545)
6. Hoos A, Britten CM, Huber C and O'Donnell-Tormey J: A methodological framework to enhance the clinical success of cancer immunotherapy. Nature Biotechnol 29: 867-870, 2011.
7. Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nature Rev 12: 265-277, 2012.
8. Sioud M and Sørensen D: Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 33: 38-45, 2003. (Pubitemid 36157641)
9. Sioud M: Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70: 516-525, 2009.
10. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, et al: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxyggenase. Science 297: 1867-1870, 2002. (Pubitemid 35024345)
11. Hwu P, Du MX, Lapointe R, Do M, Taylor MW and Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell prolifieration. J Immunol 164: 3596-3599, 2000. (Pubitemid 30169812)
12. Braun D, Longman RS and Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic cell maturation. Blood 106: 2375-2381, 2005. (Pubitemid 41510810)
13. Munn DH, Sharma MD and Hou D: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in draining-draining lymph noedes. J Clin Invest 114: 280-290, 2004. (Pubitemid 39071633)
14. Jonuleit H, Schmitt E, Stenbrink K and Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22: 394-400, 2001. (Pubitemid 32673646)
15. Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P and Andersen MH: The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 4: e6910, 2010.
16. Flatekval GF and Sioud M: Modulation of dendritic cell function and maturation with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology 128: e837-e848, 2010.
17. Guppy AE, Nathan PD and Rustin GJ: Epithelial ovarian cancer: a review of current management. Clin Oncol 17: 399-411, 2005. (Pubitemid 41136134)
18. Sæbøe-Larssen S, Fossberg E and Gaudernack G: mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 259: 191-203, 2002. (Pubitemid 33124396)
19. Suso EMI, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G and Gaudernack G: hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60: 809-818, 2011.
20. Tanaka F, Yamaguchi H, Haraguchi N, Mashino K, Ohta M, Inoue H and Mori M: Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Int J Oncol 29: 1263-1268, 2006.
21. Liu JP, Chen W, Schwarer AP and Li H: Telomerase in cancer immunotherapy. Biochim Biophys Acta 1805: 35-42, 2010.
22. Andersen MH, Svane IM, Becker JC and Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res 13: 5991-5994, 2007. (Pubitemid 350075053)
23. Moberslein M and Sioud M: Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-γ production. J Leuko Biol 91: 461-467, 2012.
24. Sioud M, Kjeldsen-Kragh J, Quayle AJ, Wiker HG, Sørskaar D, Natvig JB and Førre O: Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients, and V beta usage by specific synovial T-cell lines and fresh T cells. Scand J Immunol 34: 803-812, 1991.
25. Wobser M, Voigt H and Houben R: Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 56: 1017-1024, 2007. (Pubitemid 46675300)
26. Hodge JW, Ardiani A, Farsaci B, Kwilas AR and Gmeiro SR: The tiping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 39: 323-339, 2012.
27. Munn DH and Mellor AL: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774, 2004. (Pubitemid 39336293)
28. Shen L, Evel-Kabler K, Strube R and Chen SY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22: 1546-1553, 2004. (Pubitemid 40039457)
29. Furset G and Sioud M: Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 352: 642-649, 2007. (Pubitemid 44880303)
30. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, et al: 5′-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997, 2006.
31. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F and Reis e Sousa C: RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997-1001, 2006. (Pubitemid 44749946)
32. Poeck H, Besch R and Maihoefer C: 5′-triphosphate-siRNA: turning gene silencing and RIG-I activation against melanoma. Nat Med 14: 1256-1263, 2008.
33. Kubler K, Gehrke N and Riemann S: Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 70: 5293-5304, 2012.
34. Cheong C, Matos I and Choi JH: Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143: 416-429, 2010.
35. Fire A, Xu S and Montgomery MK: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998. (Pubitemid 28099681)
36. Kaiser PK, Symons RCA and Shah SM: A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107: 8800-8805, 2010.
37. Zamora MR, Budev M and Rolfe M: RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Resp Critical Care Med 183: 531-538, 2011.
38. DiGiusto DL, Krishnan A and Li L: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43, 2010.
39. Leachman SA, Hickerson, RP and Schwartz ME: First-in-human mutation-targeted siRNA Phase I trial of an inherited skin disorder. Mol Ther 18: 442-446, 2010.
40. Tiemann K and Rossi JJ: RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1: 142-151, 2009.
41. Behlke MA: Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670, 2006.